Skip to content

Application of bupivacaine liposome injection in percutaneous vertebroplasty

Application of bupivacaine liposome injection in percutaneous vertebroplasty

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121911
Enrollment
Unknown
Registered
2026-04-07
Start date
2025-06-03
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vertebral compression fracture

Interventions

Sponsors

Beijing Friendship Hospital ,Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Postmenopausal women or men older than 50 years; 2. Thoracolumbar vertebral compression fractures with mild or no trauma; 3. First surgery; 4. VAS score >= 6; 5. The same surgical team;

Exclusion criteria

Exclusion criteria: 1. Secondary osteoporosis, bone metastasis after bone tumor; 2. Vertebral tuberculosis, bacterial infection; 3. Severe coagulation and bleeding dysfunction that cannot be corrected; 4. Previous allergy history to bupivacaine liposomes. 5. Those who have not obtained informed consent.

Design outcomes

Primary

MeasureTime frame
VAS score at 24 hours after PVP surgery in patients treated with bupivacaine liposome injection;

Secondary

MeasureTime frame
VAS score at rest and during activity;Heart rate (HR);Mean arterial pressure (MAP);Respiratory rate (RR);Pulse oximetry saturation (SpO2);Opioid consumption during perioperative period;Length of hospital stay;Fall risk assessment score;Activities of daily living (ADL) score;Sleep duration;

Countries

China

Contacts

Public ContactFei Qi

Beijing Friendship Hospital ,Capital Medical University

spinefei@126.com+86 10 63138353

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026